Neumora Therapeutics

Neumora navacaprant fails Phase 3 as EnGene cuts 50% of staff

depression · 5 min

Neumora is discontinuing navacaprant after two Phase 3 failures in major depressive disorder and is laying off 35% of its workforce. The available evidence also shows the program’s key Phase 3 studies and the drug’s mechanism.